Prevention of UV- Induced Apoptosis by Caffeine (Caff2)
Primary Purpose
Cataract
Status
Unknown status
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Caffeine intake
No caffeine intake
Sponsored by
About this trial
This is an interventional prevention trial for Cataract focused on measuring Cataract, Caffeine
Eligibility Criteria
Inclusion Criteria:
- Age > 21 years
- Cataract
- Patients who chose pseudoanalgesia technique for cataract surgery before recruitment process
- Written informed consent prior to surgery
Exclusion Criteria:
- Age < 21 years
- Beverages containing caffeine (such as Coffee, Coca Cola, energy drinks, black or green tea) and dark chocolate consumption 1 week before surgery
- Pseudoexfoliation syndrome of the lens
- Systolic hypertension of >160 at the day of surgery
- Pregnancy (pregnancy test will be taken in women of reproductive age)
Sites / Locations
- Vienna Institute for Research in Ocular Surgery (VIROS)Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Caffeine intake
No caffeine intake
Arm Description
Caffeine is given orally prior to cataract surgery
Caffeine is not given orally prior to cataract surgery
Outcomes
Primary Outcome Measures
Number of apoptotic and viable lens epithelial cells from eyes with and without oral caffeine intake
Using a cell apoptosis and viability assay the number of apoptotic and viable lens epithelial cells is counted under a fluorescence microscope
Secondary Outcome Measures
Full Information
NCT ID
NCT03534973
First Posted
April 30, 2018
Last Updated
October 1, 2019
Sponsor
Vienna Institute for Research in Ocular Surgery
1. Study Identification
Unique Protocol Identification Number
NCT03534973
Brief Title
Prevention of UV- Induced Apoptosis by Caffeine
Acronym
Caff2
Official Title
Prevention of Experimental Ultraviolet Induced Apoptosis in Explanted Human Lens Epithelial Cells Enriched With Caffeine: a Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Unknown status
Study Start Date
April 17, 2018 (Actual)
Primary Completion Date
December 1, 2019 (Anticipated)
Study Completion Date
January 1, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vienna Institute for Research in Ocular Surgery
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis
Detailed Description
Caffeine is a worldwide consumed dietary constituent. It occurs in a variety of beverages such as coffee, tea, soft drinks and cocoa beverages, and in chocolate-based food products. In the United States there is a reported average intake of caffeine of 200 mg/d in 80 % of adults corresponding to the amount in two 5-ounce cups of coffee or four sodas. A new interest for caffeine in ophthalmology emerged with the observation that caffeine inhibits cataractogenesis.
Cataract is the leading cause of blindness worldwide and until now there is no approved drug to prevent cataract. UVR-B radiation has been identified as one of the major risk factors for age related cataract. In vitro, Varma showed that caffeine preserves ATP levels and GSH levels in the lens when exposed to UVR-B and further maintains the state of transparency in the lens. Varma moreover hypothesized that its protective effect in the lens is due to its ability to scavenge reactive oxygen species (ROS) and to suppress elevation of toxic microRNAs and consequent gene silencing. In the galactosemic rat model, Varma demonstrated that topical caffeine in vivo inhibited the formation of galactose cataract and prevented apoptosis of lens epithelial cells.
A further study presented evidence that topical caffeine also prevents in vivo UVR-B induced cataract and inhibits apoptosis of lens epithelial cells. The investigators estimated the protection factor (PF) of caffeine to 1.23. The PF is identical to PF for sunscreens; the ratio between the threshold dose of the toxic agent and the threshold dose without the toxic agent. The PF observed for topically applied caffeine was higher than the PF observed for perorally administered vitamin E (PF: 1.14) and vitamin C (PF: 1) , respectively. Only the Grx gene provides a higher PF (PF 1.3). This strongly supports that caffeine has an important antioxidant capacity in vivo.
Up to 99 % of caffeine is gastrointestinally absorbed and pharmacokinetics are comparable after oral and i.v. administration. In the liver, caffeine is metabolized by hepatic enzymes belonging to the cytochrome P-450 family, mainly CYP1A2. Major metabolites like 1-methylxanthine and 1-methyl uric acid were reported to still have significant antioxidant activity. Recently, a study confirmed the protective effect of coffee combined with additional antioxidant dietary against age-related cataract. Its hydrophobic properties allow caffeine passage over all biological membranes. A further study found that caffeine after oral intake accumulates in the lens epithelium.
The lens epithelium plays a major role in balancing water, ions and the metabolic homeostasis. Additionally, the germinative cells in the lens epithelium generate a reservoir for lens fiber cell generation. UVR-B radiation is absorbed by proteins and DNA in the lens epithelium and underlying lens fibres, causing damage to the cells. When epithelial cells are damaged, lens growth and transparency is disturbed. Michael et al. demonstrated the appearance of apoptotic lens cells after in vivo exposure to UVR-B with transmission electron microscopy. No necrotic cells were found at threshold dose. We found a peak of Apoptosis hours after UVR-B exposure.
The present study aims to investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract
Keywords
Cataract, Caffeine
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Caffeine intake
Arm Type
Active Comparator
Arm Description
Caffeine is given orally prior to cataract surgery
Arm Title
No caffeine intake
Arm Type
Sham Comparator
Arm Description
Caffeine is not given orally prior to cataract surgery
Intervention Type
Other
Intervention Name(s)
Caffeine intake
Intervention Description
Cataract surgery in eyes with prior caffeine intake
Intervention Type
Other
Intervention Name(s)
No caffeine intake
Intervention Description
Cataract surgery in eyes without prior caffeine intake
Primary Outcome Measure Information:
Title
Number of apoptotic and viable lens epithelial cells from eyes with and without oral caffeine intake
Description
Using a cell apoptosis and viability assay the number of apoptotic and viable lens epithelial cells is counted under a fluorescence microscope
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
105 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 21 years
Cataract
Patients who chose pseudoanalgesia technique for cataract surgery before recruitment process
Written informed consent prior to surgery
Exclusion Criteria:
Age < 21 years
Beverages containing caffeine (such as Coffee, Coca Cola, energy drinks, black or green tea) and dark chocolate consumption 1 week before surgery
Pseudoexfoliation syndrome of the lens
Systolic hypertension of >160 at the day of surgery
Pregnancy (pregnancy test will be taken in women of reproductive age)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Martin Kronschlaeger, MD
Phone
01 91021-57572
Email
martin.kronschlaeger@gmx.at
First Name & Middle Initial & Last Name or Official Title & Degree
Manuel Ruiß, MSc
Phone
01 91021-57564
Email
m.ruiss@viros.at
Facility Information:
Facility Name
Vienna Institute for Research in Ocular Surgery (VIROS)
City
Vienna
ZIP/Postal Code
1140
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Kronschlaeger, MD
Phone
01 91021-57572
Email
martin.kronschlaeger@gmx.at
First Name & Middle Initial & Last Name & Degree
Manuel Ruiß, Mac
Phone
01 90121-57564
Email
m.ruiss@viros.at
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Prevention of UV- Induced Apoptosis by Caffeine
We'll reach out to this number within 24 hrs